Unlock AI-driven, actionable R&D insights for your next breakthrough.

Croscarmellose Sodium Disintegration Mechanism: Molecular Dynamics, Structural Functionality, And Formulation Optimization For Rapid-Release Solid Dosage Forms

NOV 17, 202662 MINS READ

Want An AI Powered Material Expert?
Here's Patsnap Eureka Materials!
Croscarmellose sodium, an internally cross-linked sodium carboxymethyl cellulose derivative, functions as a superdisintegrant in pharmaceutical solid dosage forms through a synergistic mechanism combining rapid water wicking via its fibrous structure, volumetric swelling upon hydration, and elastic deformation recovery 2. Unlike alternative superdisintegrants such as crospovidone or sodium starch glycolate, croscarmellose sodium exhibits superior disintegration performance at low concentrations (typically 2–6% w/w) while maintaining formulation stability and organoleptic acceptability 5,7. This article provides an in-depth analysis of the physicochemical basis of its disintegration mechanism, particle engineering strategies to optimize performance, and formulation design principles for achieving tablet disintegration times below 30 seconds in aqueous media.
Want to know more material grades? Try Patsnap Eureka Material.

Molecular Composition And Structural Characteristics Of Croscarmellose Sodium

Croscarmellose sodium is synthesized via internal cross-linking of sodium carboxymethyl cellulose (NaCMC) with a degree of substitution (DS) ranging from 0.60 to 0.90 1,17. The cross-linking reaction is typically catalyzed by sulfuric acid in aqueous-organic solvent systems at controlled temperatures (40–75°C), yielding a three-dimensional polymeric network that is water-insoluble yet highly hydrophilic 17. The cross-linking agent—commonly propylene glycol or self-crosslinking under acidic conditions—creates covalent bridges between carboxymethyl cellulose chains, restricting polymer dissolution while preserving rapid water uptake capacity 1,17.

The resulting material exhibits a fibrous morphology with high specific surface area (≥0.3 m²/g for fine-particle grades) 11,12,13. This fibrous architecture is critical to the disintegration mechanism: the elongated cellulose fibrils facilitate capillary water penetration (wicking) into tablet matrices, while the cross-linked network undergoes reversible swelling without forming viscous gels that would retard disintegration 2,11. Commercially available croscarmellose sodium (e.g., Ac-Di-Sol®) typically has a median particle size (D50) of 34–86 µm, though fine-particle variants with D50 of 5–36 µm and volume mean diameter ≤40 µm have been developed to enhance disintegration kinetics in high-dose or poorly compressible formulations 2,11,12,13.

The degree of cross-linking directly influences disintegration performance: excessive cross-linking reduces swelling capacity and slows water uptake, whereas insufficient cross-linking may cause premature polymer dissolution and gel formation 1,17. Optimal pharmaceutical-grade croscarmellose sodium balances these properties to achieve rapid disintegration (typically 8–30 seconds in USP disintegration apparatus) without compromising tablet mechanical strength 2,15.

Mechanistic Pathways Of Tablet Disintegration By Croscarmellose Sodium

Wicking And Capillary Water Penetration

The fibrous structure of croscarmellose sodium creates an extensive network of capillary channels within compressed tablets 2,11. Upon contact with aqueous dissolution media, water is rapidly drawn into the tablet core via capillary action along the cellulose fibrils. This wicking mechanism is particularly effective in hydrophobic or poorly wettable formulations, where croscarmellose sodium acts as a hydrophilic conduit to facilitate water ingress 2,5. The rate of wicking is influenced by particle size distribution: finer particles (D50 < 25 µm) provide greater surface area and shorter diffusion paths, accelerating water penetration and reducing disintegration time by up to 50% compared to conventional grades (D50 ≈34 µm) at equivalent concentrations 11,12,13.

Volumetric Swelling And Internal Pressure Generation

Following water uptake, the cross-linked carboxymethyl cellulose chains undergo rapid hydration and volumetric expansion. The swelling pressure generated within the tablet matrix disrupts interparticulate bonds and propagates fracture planes, leading to tablet breakup 2,5,11. Unlike linear polymers that dissolve and form viscous barriers, the cross-linked network of croscarmellose sodium swells without significant viscosity increase, ensuring that disintegration is not hindered by gel layer formation 2,7. Quantitative swelling studies indicate that croscarmellose sodium can absorb 4–8 times its weight in water within 10–20 seconds, generating localized pressures sufficient to overcome tablet tensile strength (typically 1–3 MPa for direct-compression tablets) 5,15.

The swelling mechanism is pH-dependent: in acidic media (pH 1–3), carboxylate groups are partially protonated, reducing electrostatic repulsion and moderating swelling; in neutral to slightly alkaline media (pH 6–8), ionization of carboxylate groups enhances osmotic pressure and accelerates swelling 1,14. This pH sensitivity can be exploited in extended-release formulations where croscarmellose sodium is combined with alkaline agents (e.g., magnesium oxide) to modulate disintegration kinetics in different gastrointestinal segments 14.

Elastic Deformation Recovery

The fibrous morphology of croscarmellose sodium imparts a degree of elastic recovery upon hydration 2,11. During tablet compression, cellulose fibrils are deformed and compacted; upon water contact, the fibrils partially recover their original conformation, contributing to tablet disruption. This elastic recovery mechanism is synergistic with swelling and wicking, and is most pronounced in formulations compressed at moderate forces (5–15 kN) where fibril deformation is reversible 2,15. At very high compaction forces (>20 kN), irreversible fibril damage may occur, reducing elastic recovery and prolonging disintegration time 2.

Particle Size Engineering And Performance Optimization In Croscarmellose Sodium Formulations

Influence Of Median Particle Size On Disintegration Kinetics

Recent patent literature demonstrates that croscarmellose sodium with median particle size ≥56 µm exhibits paradoxically improved disintegration performance at high use levels (≥4% w/w) compared to conventional grades (D50 ≈34 µm) 2. Tablets containing 4–5% of coarse-grade croscarmellose sodium (D50 = 59–86 µm) compressed at 10 kN showed disintegration times of 15–25 seconds, whereas equivalent formulations with fine-grade material (D50 = 34 µm) required 35–50 seconds 2. This counterintuitive result is attributed to reduced interparticle cohesion and enhanced porosity in coarse-particle beds, facilitating water ingress and swelling-induced fracture propagation 2.

Conversely, ultra-fine croscarmellose sodium (D50 = 5–25 µm, specific surface area ≥0.3 m²/g) is advantageous in low-dose formulations (≤2% w/w) or when rapid disintegration (<10 seconds) is required 11,12,13. The high surface area and short diffusion distances in fine-particle systems accelerate wicking and swelling onset, enabling disintegration times of 8–12 seconds at 0.5–1.0% concentration 11,13. However, ultra-fine grades may exhibit poor flow properties and require co-processing with flow aids (e.g., colloidal silicon dioxide) or direct blending with microcrystalline cellulose to ensure uniform content distribution 4,6.

Co-Processed Excipient Systems For Enhanced Disintegration

Co-processing croscarmellose sodium with complementary excipients can synergistically improve both disintegration and manufacturability 4,6. A cellulose-based co-processed excipient comprising 85–95% microcrystalline cellulose and 5–15% croscarmellose sodium (spray-dried from aqueous slurry at 30–100°C) exhibits bulk density of 0.20–0.50 g/mL, excellent compressibility, and intrinsic disintegration functionality 4,6. Tablets formulated with 50–70% of this co-processed material achieve disintegration times of 15–30 seconds without additional disintegrant, simplifying formulation design and reducing manufacturing steps 4,6.

Another effective strategy involves combining croscarmellose sodium (2–4% w/w) with calcium silicate (5–10% w/w) as a disintegration promoter in wet-granulation formulations 15. Calcium silicate enhances water penetration and disrupts granule integrity, complementing the swelling action of croscarmellose sodium. Tablets containing 7% croscarmellose sodium and 27% calcium silicate (ratio 1:3.9) compressed to 3–4 kP hardness exhibited disintegration times of 8–10 seconds and friability ≤0.15%, demonstrating that high disintegrant/promoter loadings do not compromise mechanical robustness when properly balanced 15.

Formulation Design Principles For Rapid-Disintegrating Tablets With Croscarmellose Sodium

Optimal Concentration Ranges And Intragranular/Extragranular Distribution

For most immediate-release formulations, croscarmellose sodium is effective at 1–6% w/w of total tablet weight 5,7,8. At concentrations below 1%, disintegration may be incomplete or prolonged (>60 seconds); above 6%, further improvements in disintegration time are marginal, and organoleptic properties (grittiness, astringency) may deteriorate 5,8,16. The optimal concentration is typically 2–4% for direct-compression tablets and 3–5% for wet-granulation formulations 5,7,15.

Distribution of croscarmellose sodium between intragranular (within granules) and extragranular (outside granules) phases significantly affects disintegration kinetics 9,16. A 50:50 intragranular:extragranular split provides balanced performance: intragranular disintegrant promotes granule breakup, while extragranular disintegrant facilitates tablet-level disintegration 9. Formulations with 75:25 or 25:75 distributions exhibited 2-fold longer disintegration times, indicating that both granule and tablet disintegration must be addressed 9.

Wet-Granulation Processing And Croscarmellose Sodium Slurry Preparation

In wet-granulation processes, croscarmellose sodium is preferably incorporated as an aqueous slurry (5–15% w/v) used as the granulating fluid 5,7. The slurry should be prepared immediately before granulation to minimize polymer dissolution: prolonged contact with water (>30 minutes) reduces disintegrant efficacy due to partial solubilization of carboxymethyl groups 5,7. The slurry is added to a blend of active pharmaceutical ingredient (API) and excipients (e.g., microcrystalline cellulose, lactose) in a high-shear granulator, ensuring uniform coating of API particles with croscarmellose sodium 5,7.

Following granulation, the wet mass is dried (typically 40–60°C, 2–4 hours) and milled to 200–500 µm 5,7. The dried granules are then blended with extragranular croscarmellose sodium (1–3% w/w), microcrystalline cellulose (10–20% w/w), and lubricant (0.5–1.5% magnesium stearate) before compression 5,7,15. This two-stage addition strategy maximizes disintegration efficiency while maintaining granule integrity during drying and handling 5,7.

Compatibility With Fillers, Binders, And Lubricants

Croscarmellose sodium exhibits excellent compatibility with common tablet excipients, though specific interactions can modulate disintegration performance 5,7,15,16. Microcrystalline cellulose (10–50% w/w) is the preferred filler due to its compressibility, low moisture content, and synergistic disintegration effect 4,5,6,7. Mannitol (55–70% w/w, particle size 30–300 µm) is advantageous in orally disintegrating tablets (ODTs) for its pleasant taste, rapid dissolution, and minimal hygroscopicity 9,16. Lactose and sorbitol are less suitable: lactose may slow disintegration at high concentrations (>40% w/w) due to its hygroscopic nature and tendency to form hard compacts, while sorbitol can cause excessive softness and friability 16.

Binders such as polyvinylpyrrolidone (PVP) or hydroxypropyl cellulose (HPC) should be used judiciously (≤3% w/w) to avoid excessive granule strength that opposes disintegration 5,15. Lubricants must be added last and mixed briefly (1–3 minutes) to prevent hydrophobic coating of croscarmellose sodium particles, which would impair water uptake 5,7,15. Magnesium stearate (0.5–1.5% w/w) is standard; sodium stearyl fumarate (0.5–1.0% w/w) is an alternative with less hydrophobicity 4,6.

Applications Of Croscarmellose Sodium Disintegration Mechanism In Specialized Dosage Forms

Orally Disintegrating Tablets (ODTs) For Pediatric And Geriatric Populations

Croscarmellose sodium is a cornerstone excipient in ODT formulations designed to disintegrate within 30 seconds in the oral cavity without water 8,9,16. Japanese patent literature describes ODTs containing 1–4% croscarmellose sodium, 55–70% spray-dried mannitol (D50 ≈160 µm), 10–18% fine-grade microcrystalline cellulose (D50 ≈50 µm, >99% <250 µm), and 0.5–2% lubricant 16. These tablets achieve disintegration times of 10–20 seconds at 2–4 kP hardness and friability <0.2%, with pleasant mouthfeel and minimal grittiness 16.

For bitter-tasting APIs, croscarmellose sodium can serve dual roles as taste-masking coating and disintegrant 3. API particles (50–500 µm) are coated with 10–50% w/w croscarmellose sodium via fluid-bed spray coating from aqueous solution, then compressed into tablets with additional extragranular croscarmellose sodium (2–4% w/w) 3. The coating masks bitterness during oral disintegration, while the extragranular disintegrant ensures rapid tablet breakup and API release in the stomach 3.

Suspension Tablets For Extemporaneous Liquid Dosing

Croscarmellose sodium enables formulation of "suspension tablets" that disintegrate within 10–30 seconds in small volumes of water (5–20 mL) to form uniform suspensions suitable for oral administration 5,7. These formulations contain 1–6% croscarmellose sodium, 10–50% microcrystalline cellulose, and 10–50% of a co-processed microcrystalline cellulose/calcium-sodium alginate complex (75–95% MCC, 5–25% alginate) 5,7. The alginate component provides suspending properties, preventing API sedimentation after disintegration 5,7.

The superiority of croscarmellose sodium over alternative superdisintegrants (crospovidone, sodium starch glycolate) in this application is notable: crospovidone failed to provide adequate API particle coating during granulation, resulting in incomplete taste masking and slower disintegration; sodium starch glycolate developed ropy consistency in aqueous slurry, inhibiting uniform granulation 5,7. Only croscarmellose sodium achieved the required balance of rapid disintegration, uniform suspension formation, and processability 5,7.

Extended-Release Formulations Via pH-Modulated Disintegration

Paradoxically, croscarmellose sodium can be incorporated into extended-release formulations when combined with pH-modifying agents that suppress its disintegration activity in the stomach and trigger release in the intestine 14. Tablets containing API, croscarmellose sodium (3–8% w/w), sodium bicarbonate or sodium carbonate (5–15% w/w), and magnesium oxide (2–5% w/w) exhibit minimal disintegration in simulated gastric fluid (pH 1.2, <10% release in 2 hours) but rapid disintegration in simulated intestinal fluid

OrgApplication ScenariosProduct/ProjectTechnical Outcomes
FMC CORPORATION INC.High-dose immediate-release tablets requiring rapid disintegration at elevated disintegrant concentrations, particularly in direct-compression formulations.Ac-Di-Sol®Coarse-grade croscarmellose (median particle size ≥56 µm) at ≥4% w/w achieves tablet disintegration in 15-25 seconds at 10 kN compression force, demonstrating superior performance through enhanced porosity and reduced interparticle cohesion.
FMC CORPORATIONLow-dose pharmaceutical formulations and orally disintegrating tablets requiring ultra-rapid disintegration (<10 seconds) with minimal excipient loading.Ac-Di-Sol® (Fine Particle Grade)Ultra-fine croscarmellose with median particle size 5-36 µm and specific surface area ≥0.3 m²/g enables disintegration times of 8-12 seconds at 0.5-1.0% concentration through accelerated wicking and swelling onset.
Sigachi Industries LimitedDirect-compression tablet formulations requiring simplified manufacturing processes and intrinsic disintegration functionality for immediate-release solid dosage forms.Co-processed MCC-Croscarmellose ExcipientSelf-disintegrating co-processed composition containing 85-95% microcrystalline cellulose and 5-15% croscarmellose sodium with bulk density 0.20-0.50 g/mL achieves 15-30 second disintegration without additional disintegrant.
R.P. SCHERER TECHNOLOGIES INC.Orally disintegrating tablets for pediatric and geriatric populations containing bitter-tasting active pharmaceutical ingredients requiring palatability enhancement.Taste-Masked Croscarmellose Coating SystemFluid-bed coating of bitter API particles (50-500 µm) with 10-50% w/w croscarmellose sodium provides dual taste-masking and rapid disintegration functionality, eliminating need for separate enteric coatings.
SCHERING CORPORATIONHigh-strength immediate-release tablets requiring both mechanical robustness for packaging/handling and ultra-rapid disintegration for acute therapeutic applications.Wet Granulation Formulation with Calcium SilicateCombination of 7% croscarmellose sodium with 27% calcium silicate (ratio 1:3.9) achieves 8-10 second disintegration at 3-4 kP hardness with friability ≤0.15% in wet-granulated tablets.
Reference
  • Sodium croscarmellose and preparation method thereof
    PatentInactiveCN104262649A
    View detail
  • Solid forms
    PatentInactiveEP2588088A2
    View detail
  • flavor masking with croscarmellose
    PatentInactiveDK1094788T3
    View detail
If you want to get more related content, you can try Eureka.

Discover Patsnap Eureka Materials: AI Agents Built for Materials Research & Innovation

From alloy design and polymer analysis to structure search and synthesis pathways, Patsnap Eureka Materials empowers you to explore, model, and validate material technologies faster than ever—powered by real-time data, expert-level insights, and patent-backed intelligence.

Discover Patsnap Eureka today and turn complex materials research into clear, data-driven innovation!

Group 1912057372 (1).pngFrame 1912060467.png